Rowley S, Newbold K M, Gearty J, Keighley M R, Donovan I A, Neoptolemos J P
University Department of Surgery, Dudley Road Hospital, Birmingham, England, United Kingdom.
World J Surg. 1990 Jul-Aug;14(4):545-50; discussion 551. doi: 10.1007/BF01658688.
A simultaneous flow cytometric assay of the nuclear expressed protein product of the c-myc oncogene p62 and deoxyribonucleic acid (DNA) ploidy in archival paraffin-embedded tumor material was undertaken in 179 patients with colorectal cancer, followed for up to 9 years. DNA ploidy showed a survival advantage for diploid tumors (chi 2(1) = 5.39, p = 0.020) and could be used to further divide patients with Dukes' A tumors (chi 2(1) = 4.87, p = 0.027) and Dukes' C tumors (chi 2(1) = 5.33, p = 0.021). By dividing patients into 2 levels of tumor expression of p62 c-myc, there was a trend for improved survival in patients with low expression (chi 2(1) = 3.65, p = 0.056). A combination of ploidy status and p62 c-myc expression improved upon survival prediction by ploidy alone in providing 3 groups (chi 2(2) = 7.86, p = 0.0197). While these results do not suggest a replacement for the Dukes' staging for prognosis (chi 2(3) = 33.82, p less than 0.00001), they strongly support the concept that enhanced expression of c-myc oncogene is associated with the progression of colorectal cancer.
对179例结肠癌患者存档的石蜡包埋肿瘤组织进行了一项同步流式细胞术检测，检测c-myc癌基因p62的核表达蛋白产物和脱氧核糖核酸（DNA）倍体情况，并对患者进行了长达9年的随访。DNA倍体显示二倍体肿瘤具有生存优势（χ2(1)=5.39，p = 0.020），并且可用于进一步区分Dukes' A期肿瘤患者（χ2(1)=4.87，p = 0.027）和Dukes' C期肿瘤患者（χ2(1)=5.33，p = 0.021）。将患者按p62 c-myc肿瘤表达的2个水平进行划分，低表达患者有生存改善的趋势（χ2(1)=3.65，p = 0.056）。倍体状态和p62 c-myc表达相结合在预测生存方面比单纯倍体有所改善，可将患者分为3组（χ2(2)=7.86，p = 0.0197）。虽然这些结果并不表明Dukes分期在预后方面可被取代（χ2(3)=33.82，p＜0.00001），但它们有力地支持了c-myc癌基因表达增强与结肠癌进展相关的概念。
